The current status of brachytherapy in Europe − A GEC-ESTRO Brachy-HERO survey

J. G. Johansen; I. M. Jürgenliemk-Schulz; H. Haddad; J. M. Hannoun-Levi; T. P. Hellebust; B. Guix; K. Loessl; B. Pieters; C. Rao; V. Strnad; A. E. Sturdza; L. Tagliaferri; Z. Takacsi-Nagy; E. Villafranca; P. Wojcieszek; A. Rembielak; P. Niehoff

doi:10.1016/j.ctro.2024.100883

The current status of brachytherapy in Europe − A GEC-ESTRO Brachy-HERO survey

J. G. Johansen^*, I. M. Jürgenliemk-Schulz, H. Haddad, J. M. Hannoun-Levi, T. P. Hellebust, B. Guix, K. Loessl, B. Pieters, C. Rao, V. Strnad, A. E. Sturdza, L. Tagliaferri, Z. Takacsi-Nagy, E. Villafranca, P. Wojcieszek, A. Rembielak, P. Niehoff

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

A survey regarding utilisation of brachytherapy was distributed to European brachytherapy professionals. Eighty replies from 26 countries were received, two of which were outside Europe. The replies showed that brachytherapy is still widely used. The main indications for brachytherapy are gynaecological and prostate cancer, with >80 % of the responding countries performing brachytherapy for these indications. There is on average one brachytherapy centre per 0.8 million inhabitants, ranging from 0.4 per million to 2.3 per million inhabitants. The organisation of brachytherapy on national levels also varies from country to country, with less than half of the countries having a central brachytherapy registry. All in all, the survey shows that brachytherapy still plays a role on modern radiotherapy, but the field could benefit from a stronger collaboration both nationally and internationally.

Original language	English
Article number	100883
Number of pages	6
Journal	Clinical and translational radiation oncology
Volume	50
DOIs	https://doi.org/10.1016/j.ctro.2024.100883
Publication status	Published - Jan 2025

Access to Document

10.1016/j.ctro.2024.100883Licence: CC BY-NC-ND

PIIS2405630824001605Final published version, 1.15 MBLicence: CC BY-NC-ND

Cite this

Johansen, J. G., Jürgenliemk-Schulz, I. M., Haddad, H., Hannoun-Levi, J. M., Hellebust, T. P., Guix, B., Loessl, K., Pieters, B., Rao, C., Strnad, V., Sturdza, A. E., Tagliaferri, L., Takacsi-Nagy, Z., Villafranca, E., Wojcieszek, P., Rembielak, A., & Niehoff, P. (2025). The current status of brachytherapy in Europe − A GEC-ESTRO Brachy-HERO survey. Clinical and translational radiation oncology, 50, Article 100883. https://doi.org/10.1016/j.ctro.2024.100883

@article{bd74b1b478c74f5785775d86882484b3,

title = "The current status of brachytherapy in Europe − A GEC-ESTRO Brachy-HERO survey",

abstract = "A survey regarding utilisation of brachytherapy was distributed to European brachytherapy professionals. Eighty replies from 26 countries were received, two of which were outside Europe. The replies showed that brachytherapy is still widely used. The main indications for brachytherapy are gynaecological and prostate cancer, with >80 % of the responding countries performing brachytherapy for these indications. There is on average one brachytherapy centre per 0.8 million inhabitants, ranging from 0.4 per million to 2.3 per million inhabitants. The organisation of brachytherapy on national levels also varies from country to country, with less than half of the countries having a central brachytherapy registry. All in all, the survey shows that brachytherapy still plays a role on modern radiotherapy, but the field could benefit from a stronger collaboration both nationally and internationally.",

author = "Johansen, {J. G.} and J{\"u}rgenliemk-Schulz, {I. M.} and H. Haddad and Hannoun-Levi, {J. M.} and Hellebust, {T. P.} and B. Guix and K. Loessl and B. Pieters and C. Rao and V. Strnad and Sturdza, {A. E.} and L. Tagliaferri and Z. Takacsi-Nagy and E. Villafranca and P. Wojcieszek and A. Rembielak and P. Niehoff",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors",

year = "2025",

month = jan,

doi = "10.1016/j.ctro.2024.100883",

language = "English",

volume = "50",

}

Johansen, JG, Jürgenliemk-Schulz, IM, Haddad, H, Hannoun-Levi, JM, Hellebust, TP, Guix, B, Loessl, K, Pieters, B, Rao, C, Strnad, V, Sturdza, AE, Tagliaferri, L, Takacsi-Nagy, Z, Villafranca, E, Wojcieszek, P, Rembielak, A & Niehoff, P 2025, 'The current status of brachytherapy in Europe − A GEC-ESTRO Brachy-HERO survey', Clinical and translational radiation oncology, vol. 50, 100883. https://doi.org/10.1016/j.ctro.2024.100883

TY - JOUR

T1 - The current status of brachytherapy in Europe − A GEC-ESTRO Brachy-HERO survey

AU - Johansen, J. G.

AU - Jürgenliemk-Schulz, I. M.

AU - Haddad, H.

AU - Hannoun-Levi, J. M.

AU - Hellebust, T. P.

AU - Guix, B.

AU - Loessl, K.

AU - Pieters, B.

AU - Rao, C.

AU - Strnad, V.

AU - Sturdza, A. E.

AU - Tagliaferri, L.

AU - Takacsi-Nagy, Z.

AU - Villafranca, E.

AU - Wojcieszek, P.

AU - Rembielak, A.

AU - Niehoff, P.

PY - 2025/1

Y1 - 2025/1

N2 - A survey regarding utilisation of brachytherapy was distributed to European brachytherapy professionals. Eighty replies from 26 countries were received, two of which were outside Europe. The replies showed that brachytherapy is still widely used. The main indications for brachytherapy are gynaecological and prostate cancer, with >80 % of the responding countries performing brachytherapy for these indications. There is on average one brachytherapy centre per 0.8 million inhabitants, ranging from 0.4 per million to 2.3 per million inhabitants. The organisation of brachytherapy on national levels also varies from country to country, with less than half of the countries having a central brachytherapy registry. All in all, the survey shows that brachytherapy still plays a role on modern radiotherapy, but the field could benefit from a stronger collaboration both nationally and internationally.

AB - A survey regarding utilisation of brachytherapy was distributed to European brachytherapy professionals. Eighty replies from 26 countries were received, two of which were outside Europe. The replies showed that brachytherapy is still widely used. The main indications for brachytherapy are gynaecological and prostate cancer, with >80 % of the responding countries performing brachytherapy for these indications. There is on average one brachytherapy centre per 0.8 million inhabitants, ranging from 0.4 per million to 2.3 per million inhabitants. The organisation of brachytherapy on national levels also varies from country to country, with less than half of the countries having a central brachytherapy registry. All in all, the survey shows that brachytherapy still plays a role on modern radiotherapy, but the field could benefit from a stronger collaboration both nationally and internationally.

UR - http://www.scopus.com/inward/record.url?scp=85208486436&partnerID=8YFLogxK

U2 - 10.1016/j.ctro.2024.100883

DO - 10.1016/j.ctro.2024.100883

M3 - Article

AN - SCOPUS:85208486436

SN - 2405-6308

VL - 50

JO - Clinical and translational radiation oncology

JF - Clinical and translational radiation oncology

M1 - 100883

ER -

The current status of brachytherapy in Europe − A GEC-ESTRO Brachy-HERO survey

Abstract

Access to Document

Other files and links

Fingerprint

Cite this